Biopharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Solubilizers & Surfactants/Emulsifiers, Specialty Excipients, Polyols, Carbohydrates), By Region, And Segment Forecasts, 2019 - 2025

Industry Insights

The global biopharmaceutical excipients market size was valued at USD 1.67 billion in 2017.It is poised to witness a CAGR of 6.08% during the forecast period. The stability of large molecules is inherently less, as compared to small molecules. Research and investments made to address the challenges observed as a consequence of aforementioned fact are expected to drive the market in future. Lucrative growth of the biopharmaceutical industry has created potential opportunities for the conventional drug excipient developers to expand their business operations in this market.

Companies are engaged in addressing the bioavailability issues by combining innovative drug delivery technologies with APIs. For example, VitalDose EVA excipient produced by Celanese allows combination with therapeutic agents for the application as delivery vehicle for the controlled release of biologic APIs.Future demand for excipients is anticipated to be driven by the new advances in bioprocessing and biopharmaceutical industry, such as the rise in outsourcing trend, novel production methods, and reduced timelines for product launches.

In addition, manufacturers are seeking chemical research labs for the development of products with multifunctionality and enhanced performance. Introduction of strategies for improvement of manufacturing economics and overcoming the issues of stringent product development timelines is expected to fuel progress in the biopharmaceutical sector. Large molecule developers are incorporating methods for the development of biologics in various dosage forms, apart from IV solutions, which in turn, has created potential avenues for the companies to streamline their portfolio in solid excipients.

International Pharmaceutical Excipient Councils (IPECs) have played a major role in reshaping the market through active participation in the promotion of safe and effective product usage in formulations. Furthermore, companies like Merck KGaA are striving to capitalize on potential avenues in the emerging markets and thus are engaged in expanding their distribution network.

Product Insights

Carbohydrates, particularly sucrose, dextrose, and starch, led the market in the past and accounted for the largest share in global revenue. Easy availability of products at reasonable prices has resulted in wide usage of sucrose as a bulking and stabilizing agent in about 80% of the lyophilized monoclonal antibody-based formulations. In addition, starch is being conventionally used in a number of drug products owing to its well-defined safety profile. It can be modified to expand its properties, which further aids in the formulation of complex delivery systems for large molecules.

Major companies are engaged in improvement of their manufacturing processes to comply with Goods Manufacturing Practice (GMP) requirements. Companies are also embracing initiatives to align with the regulations to achieve EXCiPACT certification. For instance, in December 2015, Roquette obtained EXCiPACT certification for following products: monohydrate & anhydrous glucose, modified starches, pregelatinized starches, native starches, and other excipients.

Regional Insights

Europe accounted for the largest share of the global market in 2017, followed by North America. Presence of diversified suppliers and strong research funding in chemicals division has resulted into the estimated share of these regions in global revenue. Growth prospects for this industry in these markets are projected to be moderate in the coming years.

Emerging markets, such as India, China, and South Korea, are projected to witness lucrative growth. The anticipated rise in demand and sales for raw materials in these markets, can be attributed to the maturing biopharmaceutical industry and expanding business footprint of companies in the Asian countries.

For example, in March 2017, ABITEC entered a multi-year agreement with IMCD to sell its lipid-based products in Taiwan, India, China, and Brazil. Similarly, in December 2017, Merck KGaA signed a distribution agreement with Avanti Polar Lipids. As per the agreement, Avanti became the exclusive multinational distributor of Merck’s research lipids portfolio in India and several locations outside U.S.

Biopharmaceutical Excipients Market Share Insights

The market is observed to be consolidated in nature with the presence of a substantial number of small-, medium-, and large-sized manufacturers and suppliers. The success of this market can be greatly benefitted from the collaboration between excipient manufacturers and biopharma product developers. Such colloborations help end-users and manufacturers in identification of critical attributes of various excipient products and in selection of test methods for evaluation.

This business model of developing excipients in collaboration with the biopharmaceutical companies would help address issues associated with the production process, quality-by-design, and the bioavailability of products. This, in turn, would aid in organic revenue generation for both the parties. ABITEC Corp.; Signet Chemical Corporation Pvt. Ltd.; Roquette; Sigachi Industries Pvt. Ltd.; Meggle AG; Colorcon, Inc.; DFE Pharma; Clariant; IMCD; SPI Pharma; Pharmonix Biological Pvt. Ltd.; Spectrum Chemical Manufacturing Corp., and BASF SE are some of the key companies in the global market.

Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global biopharmaceutical excipients market report on the basis of product and region:

• Product Outlook (Volume, Tons; Revenue, USD Million, 2014 - 2025)

  • Solubilizers & Surfactants/Emulsifiers

    • Triglycerides

    • Esters

    • Others

  • Polyols

    • Mannitol

    • Sorbitol

    • Others

  • Carbohydrates

    • Sucrose

    • Dextrose

    • Starch

    • Others

  • Specialty Biopharmaceutical Excipients/Others

• Regional Outlook (Volume, Tons; Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

    • India

    • Malaysia

    • South Korea

    • Philippines

    • New Zealand

    • Australia

    • Singapore

    • Indonesia

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa